Feasibility and safety of transfemoral transcatheter aortic valve implantation performed with a percutaneous coronary intervention-like approach.

Anesthésie locale Aortic stenosis Intervention percutanée coronaire Local anaesthesia Percutaneous coronary intervention Sténose aortique TAVI Transcatheter aortic valve implantation

Journal

Archives of cardiovascular diseases
ISSN: 1875-2128
Titre abrégé: Arch Cardiovasc Dis
Pays: Netherlands
ID NLM: 101465655

Informations de publication

Date de publication:
Historique:
received: 02 09 2020
revised: 05 11 2020
accepted: 22 12 2020
pubmed: 26 4 2021
medline: 26 10 2021
entrez: 25 4 2021
Statut: ppublish

Résumé

Transfemoral percutaneous transcatheter aortic valve implantation (TF-TAVI) is a safe, reproducible and established procedure, mainly performed under local anaesthesia, which is mostly administered and monitored by a dedicated anaesthesia team (regular approach). Our centre has developed a standardized pathway of care, and eligible patients are selected for a minimalist TF-TAVI, entirely managed by operators without the presence of the anaesthesia team in the operating room, like most interventional coronary procedures ("percutaneous coronary intervention-like" approach [PCI approach]). To compare the safety and efficacy of TF-TAVI performed with the PCI approach versus the regular approach. The analysis population comprised all patients who underwent TF-TAVI with the PCI or regular approach in our institution from November 2016 to July 2019. The two co-primary endpoints were early safety composite and early efficacy composite at 30days as defined by the Valve Academic Research Consortium-2. The PCI (n=137) and Regular (n=221) approaches were compared using the propensity score based method of inverse probability of treatment weighting. No differences were observed after comparison of TAVI performed with the PCI or regular approach regarding the composite safety endpoint (7.3% vs. 11.3%; odds ratio 0.63, 95% confidence interval 0.37 to 1.07; P=0.086) or the composite efficacy endpoint (4.4% vs. 6.3%; odds ratio 0.78, 95% confidence interval 0.41 to 1.49; P=0.45). This study suggests that the efficacy and safety of TF-TAVI entirely managed by a PCI approach for selected patients are not different to those when TF-TAVI is performed with the attendance of a full anaesthesia care team. The PCI approach appears to be a safe and efficient clinical pathway, providing an appropriate and rational utilization of anaesthesiology resources, and could be used for the majority of TF-TAVI procedures.

Sections du résumé

BACKGROUND BACKGROUND
Transfemoral percutaneous transcatheter aortic valve implantation (TF-TAVI) is a safe, reproducible and established procedure, mainly performed under local anaesthesia, which is mostly administered and monitored by a dedicated anaesthesia team (regular approach). Our centre has developed a standardized pathway of care, and eligible patients are selected for a minimalist TF-TAVI, entirely managed by operators without the presence of the anaesthesia team in the operating room, like most interventional coronary procedures ("percutaneous coronary intervention-like" approach [PCI approach]).
AIM OBJECTIVE
To compare the safety and efficacy of TF-TAVI performed with the PCI approach versus the regular approach.
METHODS METHODS
The analysis population comprised all patients who underwent TF-TAVI with the PCI or regular approach in our institution from November 2016 to July 2019. The two co-primary endpoints were early safety composite and early efficacy composite at 30days as defined by the Valve Academic Research Consortium-2. The PCI (n=137) and Regular (n=221) approaches were compared using the propensity score based method of inverse probability of treatment weighting.
RESULTS RESULTS
No differences were observed after comparison of TAVI performed with the PCI or regular approach regarding the composite safety endpoint (7.3% vs. 11.3%; odds ratio 0.63, 95% confidence interval 0.37 to 1.07; P=0.086) or the composite efficacy endpoint (4.4% vs. 6.3%; odds ratio 0.78, 95% confidence interval 0.41 to 1.49; P=0.45).
CONCLUSIONS CONCLUSIONS
This study suggests that the efficacy and safety of TF-TAVI entirely managed by a PCI approach for selected patients are not different to those when TF-TAVI is performed with the attendance of a full anaesthesia care team. The PCI approach appears to be a safe and efficient clinical pathway, providing an appropriate and rational utilization of anaesthesiology resources, and could be used for the majority of TF-TAVI procedures.

Identifiants

pubmed: 33895105
pii: S1875-2136(21)00052-8
doi: 10.1016/j.acvd.2020.12.007
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

537-549

Informations de copyright

Copyright © 2021 Elsevier Masson SAS. All rights reserved.

Auteurs

Tom Denimal (T)

Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, Cardiology, Institut Cœur Poumon, CHU de Lille, Université Lille, 59037 Lille, France.

Cédric Delhaye (C)

Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, Cardiology, Institut Cœur Poumon, CHU de Lille, Université Lille, 59037 Lille, France.

Adeline Piérache (A)

ULR 2694, METRICS: Évaluation des Technologies de Santé et des Pratiques Médicales, Université de Lille, Département de Biostatistiques, CHU de Lille, 59000 Lille, France.

Emmanuel Robin (E)

Anesthésie et Réanimation Cardiovasculaire, CHU de Lille, 59037 Lille, France.

Thomas Modine (T)

Hôpital Cardiologique Haut-Lévêque, CHU de Bordeaux, 33600 Pessac, France.

Mouhamed Moussa (M)

Anesthésie et Réanimation Cardiovasculaire, CHU de Lille, 59037 Lille, France.

Arnaud Sudre (A)

Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, Cardiology, Institut Cœur Poumon, CHU de Lille, Université Lille, 59037 Lille, France.

Mohamad Koussa (M)

Chirurgie Cardiaque, CHU de Lille, 59037 Lille, France.

Nicolas Debry (N)

Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, Cardiology, Institut Cœur Poumon, CHU de Lille, Université Lille, 59037 Lille, France.

Thibault Pamart (T)

Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, Cardiology, Institut Cœur Poumon, CHU de Lille, Université Lille, 59037 Lille, France.

Nicolas Lamblin (N)

Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, Cardiology, Institut Cœur Poumon, CHU de Lille, Université Lille, 59037 Lille, France; Unité de Soins Intensif Cardiologiques, CHU de Lille, 59037 Lille, France; Hôpital Cardiologique Haut-Lévêque, CHU de Bordeaux, 33600 Pessac, France.

Gilles Lemesle (G)

Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, Cardiology, Institut Cœur Poumon, CHU de Lille, Université Lille, 59037 Lille, France; Unité de Soins Intensif Cardiologiques, CHU de Lille, 59037 Lille, France.

Hugues Spillemaeker (H)

Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, Cardiology, Institut Cœur Poumon, CHU de Lille, Université Lille, 59037 Lille, France.

Basile Verdier (B)

Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, Cardiology, Institut Cœur Poumon, CHU de Lille, Université Lille, 59037 Lille, France.

Sina Porouchani (S)

Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, Cardiology, Institut Cœur Poumon, CHU de Lille, Université Lille, 59037 Lille, France.

Alessandro Cosenza (A)

Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, Cardiology, Institut Cœur Poumon, CHU de Lille, Université Lille, 59037 Lille, France.

Antoine Bical (A)

Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, Cardiology, Institut Cœur Poumon, CHU de Lille, Université Lille, 59037 Lille, France.

Guillaume Schurtz (G)

Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, Cardiology, Institut Cœur Poumon, CHU de Lille, Université Lille, 59037 Lille, France; Unité de Soins Intensif Cardiologiques, CHU de Lille, 59037 Lille, France.

Julien Labreuche (J)

ULR 2694, METRICS: Évaluation des Technologies de Santé et des Pratiques Médicales, Université de Lille, Département de Biostatistiques, CHU de Lille, 59000 Lille, France.

Julien Ternacle (J)

Hôpital Cardiologique Haut-Lévêque, CHU de Bordeaux, 33600 Pessac, France.

Vincent Balmette (V)

Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, Cardiology, Institut Cœur Poumon, CHU de Lille, Université Lille, 59037 Lille, France.

David Aouate (D)

Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, Cardiology, Institut Cœur Poumon, CHU de Lille, Université Lille, 59037 Lille, France.

Thomas Denis (T)

Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, Cardiology, Institut Cœur Poumon, CHU de Lille, Université Lille, 59037 Lille, France.

Dany Janah (D)

Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, Cardiology, Institut Cœur Poumon, CHU de Lille, Université Lille, 59037 Lille, France.

Habib Sylla (H)

Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, Cardiology, Institut Cœur Poumon, CHU de Lille, Université Lille, 59037 Lille, France.

Benjamin Roy (B)

Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, Cardiology, Institut Cœur Poumon, CHU de Lille, Université Lille, 59037 Lille, France.

Jacques Desbordes (J)

Anesthésie et Réanimation Cardiovasculaire, CHU de Lille, 59037 Lille, France.

Eric Van Belle (E)

Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, Cardiology, Institut Cœur Poumon, CHU de Lille, Université Lille, 59037 Lille, France. Electronic address: ericvanbelle@aol.com.

Flavien Vincent (F)

Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, Cardiology, Institut Cœur Poumon, CHU de Lille, Université Lille, 59037 Lille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH